Oral analogues of GLP-1: perspectives on glycemic control and cardiorenal risk in patients with type 2 diabetes mellitus

At present, type 2 diabetes mellitus (T2DM) is the leading cause of end-stage kidney disease. The management of T2DM in recent years has moved from a glucocentric approach to a global approach with the priority of introducing treatments that offer renal and cardiovascular protection. In this article, we review in depth the pharmacokinetics and pharmacodynamics of the first oral analog of glucagon-like peptide-1 (oral semaglutide) in comparison with its subcutaneous formulation. The knowledge and implementation of these drugs will be very useful in daily clinical practice

• Autores: Rico-Fontalvo, Jorge; daza arnedo, rodrigo andres; Vázquez Jiménez, Lourdes Carolina; Rodríguez-Yánez, Tomas; Raad Sarabia, Maria Isabel; TOAPANTA, NÉSTOR; Pérez, Rafael V.; Montejo-Hernández, Juan; Soler, María J.
• Fecha de publicación: 2024
• Institución: Universidad Simón Bolívar
• Repositorio: Repositorio Digital USB
• Idioma: eng
• OAI Identifier: oai:bonga.unisimon.edu.co:20.500.12442/16665
• Acceso en línea: https://hdl.handle.net/20.500.12442/16665; http://dx.doi.org/10.24875/NEFRO.M24000021; https://www.nefrologialatinoamericana.com/frame_eng.php?id=120
• Palabra clave: Diabetes mellitus; Glucagon-like peptide 1 receptor analogs; Semaglutide; Diabetes Mellitus; Análogos del receptor del péptido similar al glucagón tipo 1; Semaglutida
• Rights: openAccess
• License: Attribution-NonCommercial-NoDerivatives 4.0 International